A Rees1, A Zekite1, C Bunce1, P J Patel1. 1. NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.
Abstract
PURPOSE: The purpose of the study was to determine what proportion of new certifications between 1 April 2007 and 31 March 2008 could be attributed to age-related macular degeneration (AMD) and to describe the AMD-certified population in England and Wales. METHODS: An electronic version of the Certificate of Vision Impairment form (CVI), the ECVI, was used at the certifications office to transfer information from the paper-based certificates into a database. The electronic certifications data set was queried for all certificates completed between 1 April 2007 and 31 March 2008 with the main cause of certifiable visual loss being AMD or with the main cause of certifiable visual loss being multiple pathology but a contributory cause being AMD. The electronic data set was adapted so that a distinction could be made between geographic atrophy (GA) and neovascular AMD (nAMD). RESULTS: The Certifications Office received 23 185 CVIs between April 2007 and March 2008, of whom 9823 (42%) were people registered severely sight impaired (SSI) and 12 607 (52%) were certified as sight impaired (SI). AMD contributed to 13 000 causes of registration on the CVI forms during this period and was the main cause in 11 015 people. In these 11 015 people, GA accounted for 49.3%, nAMD 35.1%, and AMD not specified 15.7%. CONCLUSIONS: The data in this report provide detailed information on CVI registration due to AMD before the widespread adoption of ranibizumab therapy in NHS practice and provide an insight into the burden of vision loss due to AMD at a time of great change in the management of nAMD.
PURPOSE: The purpose of the study was to determine what proportion of new certifications between 1 April 2007 and 31 March 2008 could be attributed to age-related macular degeneration (AMD) and to describe the AMD-certified population in England and Wales. METHODS: An electronic version of the Certificate of Vision Impairment form (CVI), the ECVI, was used at the certifications office to transfer information from the paper-based certificates into a database. The electronic certifications data set was queried for all certificates completed between 1 April 2007 and 31 March 2008 with the main cause of certifiable visual loss being AMD or with the main cause of certifiable visual loss being multiple pathology but a contributory cause being AMD. The electronic data set was adapted so that a distinction could be made between geographic atrophy (GA) and neovascular AMD (nAMD). RESULTS: The Certifications Office received 23 185 CVIs between April 2007 and March 2008, of whom 9823 (42%) were people registered severely sight impaired (SSI) and 12 607 (52%) were certified as sight impaired (SI). AMD contributed to 13 000 causes of registration on the CVI forms during this period and was the main cause in 11 015 people. In these 11 015 people, GA accounted for 49.3%, nAMD 35.1%, and AMD not specified 15.7%. CONCLUSIONS: The data in this report provide detailed information on CVI registration due to AMD before the widespread adoption of ranibizumab therapy in NHS practice and provide an insight into the burden of vision loss due to AMD at a time of great change in the management of nAMD.
Authors: Joseph R Betancourt; Alexander R Green; J Emilio Carrillo; Owusu Ananeh-Firempong Journal: Public Health Rep Date: 2003 Jul-Aug Impact factor: 2.792
Authors: Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Daniel F Martin; Maureen G Maguire; Stuart L Fine; Gui-shuang Ying; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Maryann Redford; Frederick L Ferris Journal: Ophthalmology Date: 2012-05-01 Impact factor: 12.079
Authors: David M Brown; Mark Michels; Peter K Kaiser; Jeffrey S Heier; Judy P Sy; Tsontcho Ianchulev Journal: Ophthalmology Date: 2009-01 Impact factor: 12.079
Authors: Cesar Garriga; Michael Pazianas; Samuel Hawley; Antonella Delmestri; Daniel Prieto-Alhambra; Cyrus Cooper; Andrew Judge Journal: Ann N Y Acad Sci Date: 2018-01-24 Impact factor: 5.691
Authors: David S Boyer; Ursula Schmidt-Erfurth; Menno van Lookeren Campagne; Erin C Henry; Christopher Brittain Journal: Retina Date: 2017-05 Impact factor: 4.256
Authors: F Ziemssen; N Feltgen; F G Holz; R Guthoff; A Ringwald; T Bertelmann; A Wiedon; C Korb Journal: BMC Ophthalmol Date: 2017-01-19 Impact factor: 2.209
Authors: Praveen J Patel; Focke Ziemssen; Eugene Ng; Anushini Muthutantri; David Silverman; Elizabeth A Tschosik; Ronald A Cantrell Journal: Clin Ophthalmol Date: 2020-01-08
Authors: K N Le; L Gibiansky; M van Lookeren Campagne; J Good; T Davancaze; K M Loyet; A Morimoto; E C Strauss; J Y Jin Journal: CPT Pharmacometrics Syst Pharmacol Date: 2015-10-08
Authors: Rebecca L Thomas; Stephen D Luzio; Rachel V North; Sanjiv Banerjee; Antra Zekite; Catey Bunce; David R Owens Journal: BMJ Open Date: 2017-07-18 Impact factor: 2.692